🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Paul DiSilvestro

Providence College

ORCID: 0000-0003-2711-6663

Also affiliated with Brown University, Women & Infants Hospital of Rhode Island

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.870Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors

Gynecologic Oncology(2023)10.1016/j.ygyno.2022.12.017
Top 23%
0.870DataRank
Top 23%21 citations

Tracy E. Crane, Austin Miller, Michael A. Gold, Matthew A. Powell, Kristin Bixel +15 more

Papers

Driven by 11 papers — median percentile 77. Top paper: “Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors”.

Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors

Gynecologic Oncology(2023)10.1016/j.ygyno.2022.12.017
Top 23%
0.870DataRank
Top 23%21 citations

Tracy E. Crane, Austin Miller, Michael A. Gold, Matthew A. Powell, Kristin Bixel +15 more

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study

Journal of Clinical Oncology(2024)10.1200/jco.23.02076
N/A
0.644DataRank · unranked
20 citations

Ronald J. Buckanovich, Michael W. Sill, Robert S. Mannel, Joan L. Walker, Paul DiSilvestro +13 more

A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5501
N/A
0.512DataRank · unranked
9 citations

Ronald J. Buckanovich, Michael W. Sill, Robert S. Mannel, Joan L. Walker, Paul DiSilvestro +13 more

Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5502
N/A
0.396DataRank · unranked
13 citations

Wei Deng, Loren K. Mell, Debra L. Richardson, Joan L. Walker, Laura L. Holman +15 more

Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.03.005
N/A
0DataRank · unranked
13 citations

Helen Huang, Bradley J. Monk, Yong-Beom Kim, Moon‐Hong Kim, Paul DiSilvestro +17 more

A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.03.003
N/A
0DataRank · unranked
9 citations

Michael W. Sill, Paola A. Gehrig, Jason D. Merker, David L. Corcoran, Adam D. Pfefferle +15 more

The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes

Scientific Reports(2020)10.1038/s41598-020-65353-x
N/A
0DataRank · unranked
37 citations

Jenna Emerson, Ashley Borgstadt, Lindsey Beffa, Matthew T. Oliver, Virginia Hovanesian +8 more

Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.03.094
N/A
0DataRank · unranked
0 citations

Danielle Enserro, Heather A. Lankes, Kyle C. Strickland, Rebecca A. Previs, Matthew Powell +19 more

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer

Obstetrical & Gynecological Survey(2020)10.1097/ogx.0000000000000777
N/A
0DataRank · unranked
6 citations

Nick M. Spirtos, Danielle Enserro, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong +19 more

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol

UNC Libraries(2020)10.17615/5jcw-ca69
N/A
0DataRank · unranked
0 citations

David S. Miller, Steven Waggoner, Robert P. Edwards, Saketh R. Guntupalli, Matthew A. Powell +13 more

Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.03.027
N/A
0DataRank · unranked
20 citations

Danielle Enserro, Matthew S. Block, Steven Waggoner, Linda Duska, Andrea E. Wahner-Hendrickson +11 more